Lantern Pharma Unveils Next Phase of withZeta.ai Platform, Introducing Multi-Agent AI and Computational Biology Tools

Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, has announced the next phase of development for its withZeta.ai platform, which includes the planned launch of ZetaSwarm, an autonomous multi-agent AI research system, and ZetaOmics, a computational biology and multi-omic analytics toolkit. These new capabilities are designed to support institutional oncology research and drug discovery workflows, according to a press release.

The withZeta.ai platform is Lantern's multi-agentic AI co-scientist platform, now commercially available as a subscription-based research platform for the global biomedical and drug development community. This represents a new revenue stream for the company. The expansion introduces enterprise-grade capabilities aimed at streamlining complex research processes.

Lantern Pharma is a clinical-stage precision oncology company that leverages AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. The company's clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.

The announcement highlights the growing role of AI in drug development, particularly in oncology, where data complexity and the need for precision are paramount. By introducing autonomous multi-agent AI systems and advanced computational biology tools, Lantern aims to accelerate the identification of novel therapies and biomarkers, potentially reducing the time and cost associated with traditional drug discovery.

Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company's focus on integrating AI into oncology research positions it at the forefront of precision medicine, addressing significant unmet needs in cancer treatment.

For more information, visit the company's newsroom at https://ibn.fm/LTRN.